NAD footcare case
This article was originally published in The Tan Sheet
Executive Summary
Profoot Footcare Products' labeling claim that Triad Insoles "relieves knee, leg and back pain" should be discontinued due to lack of supporting scientific evidence, National Advertising Division says in recent NAD Case Reports. Dr. Scholl's marketer Schering-Plough challenged the claim, asserting it is "unqualified and overly broad as it does not distinguish" between different types of pain. Although Profoot explained the Triad design "incorporates a cupped heel for foot stability and an anatomically conforming supportive arch" to alleviate joint pressure, NAD agrees with Schering based on lack of clinical data. Profoot, while disagreeing, said it would amend the claim in future packaging...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.